Kalyan Handique


Kalyan Handique is currently the CEO of DeNovo Sciences, a cancer diagnostics start-up. Prior to joining DeNovo Sciences, Kalyan co-founded HandyLab, a start-up molecular diagnostic company which was recently acquired by Becton Dickinson (BD) Diagnostic Systems in a landmark deal valued at more than $275 Million. He served in a variety of roles including President (2000-2001), CTO (2000-2009) and Board Member (2000-2009) for HandyLab. He was pivotal in forming the vision, vibrant culture and team and was a key contributor in HandyLab’s successful entrepreneurial journey from start-to-exit. Contributions included: technology transfer, raising venture capital and government grants, growing the team, developing intellectual property, strategic collaborations, developing and launching FDA approved molecular diagnostics platforms to the eventual sale of the company. After HandyLab’s sale to BD, Kalyan served as the VP of R&D Systems Development for BD Diagnostics from 2009-2011.

Kalyan has a Ph.D. in Chemical Engineering from the University of Michigan with Prof Mark Burns as his adviser and received a Bachelors in Chemical Engineering from IIT Bombay in 1995. Kalyan is active in the entrepreneurial community and serves as an adviser for the ZL Fund, Augment Ventures, Wireless Integrated Microsystems and sits on the board of 3D Biomatrix.